{"id":"W4404910188","doi":"10.1016/s1470-2045(24)00673-9","title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Fulvestrant; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Breast cancer; Cancer; Cohort; Regimen; Letrozole; Clinical endpoint; Clinical trial; Aromatase; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002456793,0.001325246,0.002603295,0.0004937172,0.0003706247,0.001305195,0.0007036589,0.001182029,0.002534253],"category_scores_gemma":[0.001685073,0.0004382594,0.002310492,0.0005309628,0.0009989429,0.001279512,0.0003207184,0.002257217,0.0006067664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001121306,"about_ca_system_score_gemma":0.0008234023,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00151328,"about_ca_topic_score_gemma":0.00309087,"domain_scores_codex":[0.9991769,0.0004056757,0.00004126032,0.0001257487,0.00006803528,0.0001824043],"domain_scores_gemma":[0.9989303,0.0003571307,0.0002005891,0.0001456037,0.00006529412,0.0003011851],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9352004,0.01057011,0.005342665,0.0004946513,0.002526078,0.000108182,0.0001246194,0.0007901019,0.007393215,0.0001210412,0.0007658472,0.03656309],"study_design_scores_gemma":[0.6185454,0.3508011,0.02340913,0.00005702629,0.002415473,0.0002121266,0.0001304552,0.0006398916,0.001678255,0.0002448729,0.001819115,0.00004710983],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950352,0.00298578,0.0001936872,0.0001709549,0.0001126208,0.0003072796,0.0004879405,0.00002263264,0.0006840197],"genre_scores_gemma":[0.9937384,0.00220556,0.0004660321,0.0004613168,0.0002131384,0.0003292201,0.001358738,0.00001673613,0.001210813],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002603295,"threshold_uncertainty_score":0.01299298,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04917139460894078,"score_gpt":0.4071316979650551,"score_spread":0.3579603033561143,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}